Suppressing RET activity using Sunitinib, a clinically-approved tyrosine kinase inhibitor, rescued differentiation in both DUX4-expressing murine myoblasts and in FSHD patient-derived myoblasts. This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.